Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
作者信息
Goetz Matthew P, Brauch Hiltrud, Ratain Mark J, Cox Nancy J, Nakamura Yusuke, Weinshilboum Richard, Ingle James N
机构信息
Affiliations of authors: Department of Oncology (MPG, JNI) and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, RW), Mayo Clinic, Rochester, MN; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (HB); The University of Chicago, Chicago, IL (MJR, NJC, YN).
出版信息
J Natl Cancer Inst. 2014 Apr 3;106(5):dju063. doi: 10.1093/jnci/dju063.
Abstract
摘要
相似文献
1
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.关于：肿瘤来源DNA与种系DNA中CYP2D6基因型的一致性。
J Natl Cancer Inst. 2014 Apr 3;106(5):dju063. doi: 10.1093/jnci/dju063.
2
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.从肿瘤来源的和种系 DNA 中获得的 CYP2D6 基因型的一致性。
J Natl Cancer Inst. 2013 Sep 4;105(17):1332-4. doi: 10.1093/jnci/djt204. Epub 2013 Aug 19.
3
Re: CYP2D6 genotyping and the use of tamoxifen in breast cancer.关于：CYP2D6基因分型及他莫昔芬在乳腺癌中的应用。
J Natl Cancer Inst. 2014 Feb;106(2):djt379. doi: 10.1093/jnci/djt379. Epub 2014 Jan 9.
4
CYP2D6 genotyping and the use of tamoxifen in breast cancer.CYP2D6基因分型与他莫昔芬在乳腺癌中的应用
J Natl Cancer Inst. 2013 Sep 4;105(17):1267-9. doi: 10.1093/jnci/djt221. Epub 2013 Aug 19.
5
Response.
J Natl Cancer Inst. 2014 Feb;106(2):djt380. doi: 10.1093/jnci/djt380. Epub 2014 Jan 9.
6
Response.
J Natl Cancer Inst. 2014 Apr 3;106(5):dju064. doi: 10.1093/jnci/dju064.
7
Response.回应。
J Natl Cancer Inst. 2014 Apr 3;106(5):dju065. doi: 10.1093/jnci/dju065.
8
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.细胞色素P-450 2D6（CYP2D6）基因型与他莫昔芬治疗患者的乳腺癌复发：评估杂合性缺失的重要性
Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17.
9
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.乳腺癌中CYP2D6基因座杂合性缺失：对种系药物遗传学研究的启示。
J Natl Cancer Inst. 2014 Dec 8;107(2):dju401. doi: 10.1093/jnci/dju401.
10
Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.回复：乳腺癌中CYP2D6基因座杂合性缺失：对种系药物遗传学研究的启示。
J Natl Cancer Inst. 2015 Mar 26;107(5). doi: 10.1093/jnci/djv065. Print 2015 May.
引用本文的文献
1
The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.ESR1 基因中 PvuII 的变异 T 等位基因是早期乳腺癌生存的预后标志物。
Sci Rep. 2021 Feb 5;11(1):3249. doi: 10.1038/s41598-021-82002-z.
2
CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.细胞色素P450 2D6基因分型与他莫昔芬：非前瞻性研究的相关考量
Clin Pharmacol Ther. 2014 Aug;96(2):141-4. doi: 10.1038/clpt.2014.99.
本文引用的文献
1
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.CYP2D6 基因型与辅助他莫昔芬：异质研究人群的荟萃分析。
Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.
2
CYP2D6 genotyping and the use of tamoxifen in breast cancer.CYP2D6基因分型与他莫昔芬在乳腺癌中的应用
J Natl Cancer Inst. 2013 Sep 4;105(17):1267-9. doi: 10.1093/jnci/djt221. Epub 2013 Aug 19.
3
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.从肿瘤来源的和种系 DNA 中获得的 CYP2D6 基因型的一致性。
J Natl Cancer Inst. 2013 Sep 4;105(17):1332-4. doi: 10.1093/jnci/djt204. Epub 2013 Aug 19.
4
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.细胞色素P450 2D6基因分型与他莫昔芬活性：理解方法学质量的研究间变异性
Clin Pharmacol Ther. 2013 Aug;94(2):185-7. doi: 10.1038/clpt.2013.66.
5
CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.CYP2D6基因分型不应被用于确定绝经后乳腺癌患者的内分泌治疗方案。
Clin Pharmacol Ther. 2013 Aug;94(2):183-5. doi: 10.1038/clpt.2013.102.
6
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.细胞色素P450 2D6（CYP2D6）基因分型不应用于决定绝经后乳腺癌患者的他莫昔芬治疗方案。
J Clin Oncol. 2013 Jul 20;31(21):2753-5. doi: 10.1200/JCO.2013.49.4278. Epub 2013 Jun 17.
7
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.CYP2D6 代谢与奥地利乳腺癌和结直肠癌研究组试验（ABCSG 8）的患者结局。
Clin Cancer Res. 2013 Jan 15;19(2):500-7. doi: 10.1158/1078-0432.CCR-12-2153. Epub 2012 Dec 4.
8
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.他莫昔芬在绝经后乳腺癌中的应用：细胞色素P450 2D6起重要作用。
J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.
9
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.关于：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31.
10
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验 以及 回复：CYP2D6和UGT2B7基因分型与他莫昔芬治疗的乳腺癌患者复发风险
J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.
Zotero 插件